RAF Kinases in Cancer: A Moving Target and Degradation Therapy.
作者信息
Kargbo Robert B
机构信息
Usona Institute, 277 Granada Drive, San Luis Obispo, California 93401-7337, United States.
出版信息
ACS Med Chem Lett. 2020 Jun 22;11(7):1369-1370. doi: 10.1021/acsmedchemlett.0c00299. eCollection 2020 Jul 9.
Abstract
摘要
相似文献
1
RAF Kinases in Cancer: A Moving Target and Degradation Therapy.癌症中的RAF激酶：一个动态靶点与降解疗法
ACS Med Chem Lett. 2020 Jun 22;11(7):1369-1370. doi: 10.1021/acsmedchemlett.0c00299. eCollection 2020 Jul 9.
2
Bag-1 stimulates Bad phosphorylation through activation of Akt and Raf kinases to mediate cell survival in breast cancer.Bag-1 通过激活 Akt 和 Raf 激酶来刺激 Bad 磷酸化，从而介导乳腺癌细胞的存活。
BMC Cancer. 2019 Dec 28;19(1):1254. doi: 10.1186/s12885-019-6477-4.
3
Targeting the Raf kinases in human cancer: the Raf dimer dilemma.靶向人类癌症中的 Raf 激酶：Raf 二聚体难题。
Br J Cancer. 2018 Jan;118(1):3-8. doi: 10.1038/bjc.2017.399. Epub 2017 Dec 14.
4
c-Raf in KRas Mutant Cancers: A Moving Target.c-Raf 在 KRas 突变型癌症中的作用：一个移动的靶点。
Cancer Cell. 2018 Feb 12;33(2):158-159. doi: 10.1016/j.ccell.2018.01.017.
5
Unraveling the interplay between RAS/RAF/MEK/ERK signaling pathway and autophagy in cancer: From molecular mechanisms to targeted therapy.解析 RAS/RAF/MEK/ERK 信号通路与癌症自噬的相互作用：从分子机制到靶向治疗。
Biochem Pharmacol. 2023 Nov;217:115842. doi: 10.1016/j.bcp.2023.115842. Epub 2023 Oct 5.
6
Selective Raf inhibition in cancer therapy.癌症治疗中的选择性Raf抑制
Expert Opin Ther Targets. 2007 Dec;11(12):1587-609. doi: 10.1517/14728222.11.12.1587.
7
It takes two to tango--signalling by dimeric Raf kinases.探戈需两人共舞——二聚体Raf激酶的信号传导
Mol Biosyst. 2013 Apr 5;9(4):551-8. doi: 10.1039/c2mb25393c.
8
Negative feedback by conserved kinases patterns the degradation of Raf in vulval fate patterning.保守激酶的负反馈调节 Raf 的降解，从而影响体腔命运图式的形成。
Development. 2020 Dec 23;147(24):dev195941. doi: 10.1242/dev.195941.
9
Activated Raf-1 causes growth arrest in human small cell lung cancer cells.活化的Raf-1可导致人小细胞肺癌细胞生长停滞。
J Clin Invest. 1998 Jan 1;101(1):153-9. doi: 10.1172/JCI831.
10
RNF43 Inactivation Enhances the B-RAF/MEK Signaling and Creates a Combinatory Therapeutic Target in Cancer Cells.环指蛋白 43（RNF43）失活增强了 B-RAF/MEK 信号通路，并在癌细胞中创造了一个联合治疗靶点。
Adv Sci (Weinh). 2024 Mar;11(12):e2304820. doi: 10.1002/advs.202304820. Epub 2024 Jan 15.
本文引用的文献
1
RAF kinase dimerization: implications for drug discovery and clinical outcomes.RAF 激酶二聚化：对药物发现和临床结果的影响。
Oncogene. 2020 May;39(21):4155-4169. doi: 10.1038/s41388-020-1263-y. Epub 2020 Apr 8.
2
Treatment Options for Advanced Melanoma After Anti-PD-1 Therapy.抗 PD-1 治疗后晚期黑色素瘤的治疗选择。
Curr Oncol Rep. 2020 Mar 20;22(4):38. doi: 10.1007/s11912-020-0894-z.
3
Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy.针对癌症治疗的异常 RAS/RAF/MEK/ERK 信号通路。
Cells. 2020 Jan 13;9(1):198. doi: 10.3390/cells9010198.
4
Mutations That Confer Drug-Resistance, Oncogenicity and Intrinsic Activity on the ERK MAP Kinases-Current State of the Art.赋予 ERK MAP 激酶耐药性、致癌性和固有活性的突变——最新进展。
Cells. 2020 Jan 6;9(1):129. doi: 10.3390/cells9010129.
5
Proliferative signaling by ERBB proteins and RAF/MEK/ERK effectors in polycystic kidney disease.ERBB 蛋白和 RAF/MEK/ERK 效应物在多囊肾病中的增殖信号转导。
Cell Signal. 2020 Mar;67:109497. doi: 10.1016/j.cellsig.2019.109497. Epub 2019 Dec 9.
6
Nanosized Modification Strategies for Improving the Antitumor Efficacy of MEK Inhibitors.纳米级修饰策略提高 MEK 抑制剂的抗肿瘤疗效。
Curr Drug Targets. 2020;21(3):228-251. doi: 10.2174/1389450120666190807143245.
Zotero 插件